NEW YORK, May 13, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Class Period: November 14, 2016 - February 28, 2019 Deadline: May 13, 2019 For more info:www.bgandg.com/crbp
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Corbus improperly changed the primary efficacy endpoint for the clinical study of its drug candidate, Lenabasum, after the results were unblinded to Corbus; (2) Corbus reported a one-sided p value, not the traditional two-sided p value normally reported in clinical trials, in an effort to conceal the fact that the study results did not have statistical significance; and (3) as a result, Corbus' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
NIO Inc. (NYSE: NIO) Class Period: September 12, 2018 - March 5, 2019 Deadline: May 13, 2019 For more info:www.bgandg.com/nio
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) NIO would not be building its own manufacturing plant and would instead continue to rely on a little-known Chinese state-owned auto manufacturer, JAC Auto, to manufacture its electric vehicles; (2) reductions in government subsidies for electric cars would materially impact NIO's sales; and (3) as a result, defendants' statements about NIO's business, operations, and prospects were materially false and misleading at all relevant times.
Corcept Therapeutics Incorporated (NASDAQ:CORT) Class Period: August 2, 2017 - February 5, 2019 Deadline: May 13, 2019 For more info:www.bgandg.com/cort
The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) Corcept had improperly paid doctors to promote its drug, Korlym; (2) Corcept aggressively promoted Korlym for off-label uses; (3) Corcept's sole specialty pharmacy was a related party; (4) Corcept artificially inflated its revenue and sales using illicit sales practices through a related party; (5) such practices were reasonably likely to lead to regulatory scrutiny; and (6) as a result, defendants' positive statements about Corcept's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
